• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cardiff Oncology Inc.

    4/30/25 4:00:05 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDF alert in real time by email
    DEFA14A 1 crdf_defa14a_2025.htm DEFA14A DEFA14A

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

    (Amendment No. )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant o

     

    Check the appropriate box:

    o

    Preliminary Proxy Statement

    o

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    o

    Definitive Proxy Statement

    x

    Definitive Additional Materials

    o

    Soliciting Material under §240.14a-12

     

    Cardiff Oncology, Inc.

     

     

     

     

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    x

    No fee required.

     

     

     

    o

    Fee paid previously with preliminary materials.

     

     

     

     

    o

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

     


     

    img232721228_0.jpg

     

     

    NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS

     

    The Annual Meeting of Stockholders of Cardiff Oncology, Inc. will be held on June 26, 2025, at 9:00 a.m. local time at the Company’s offices located at

    11055 Flintkote Avenue, San Diego, California 92121

     

     

    PROXY STATEMENT AND 2024 ANNUAL REPORT ON FORM 10-K ARE AVAILABLE AT:

    https://annualgeneralmeetings.com/crdf2025

     

     

    Dear Stockholder:

     

    The Annual Meeting of Stockholders of Cardiff Oncology, Inc. has been called to consider and act upon the following

    matters:

     

    Proposal 1: Election of seven (7) Directors;

    Proposal 2: Ratification of BDO USA, P.C. as Cardiff Oncology’s independent registered public accountants for fiscal year ending December 31, 2025;

    Proposal 3: Approve an amendment to the Company’s 2021 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 12,150,000 shares from 8,150,000 shares; and

    Proposal 4: Approve, on an advisory basis, the compensation of the Company’s named executive officers.

     

     

    Our Board of Directors recommends a vote “FOR” all nominees listed in proposal 1 and “FOR” proposals 2, 3 and 4.

     

    You are receiving this communication because you hold shares in the company named above. Complete proxy materials,

    including the proxy card, are available to you on-line at https://annualgeneralmeetings.com/crdf2025 or upon your request by e-mail or first-class mail. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    This is not a ballot. You cannot use this notice to vote your shares. You may vote on-line, by mail or in person. If you wish to vote on-line, you will need your “Control Number” (which can be found in the bottom right hand corner of this notice) and the web address, all of which will be included with or on the proxy card located on the Internet website stated above or mailed to you at your request. No other personal information will be required in order to vote in this manner. If you wish to vote by mail, simply print out the proxy card located on the Internet website stated above, mark the proxy card accordingly, sign and return it to us at the address indicated on the proxy card. If you wish to vote in person at the Annual Meeting of Stockholders, simply check the box on the proxy card that you plan to attend. Your proxy card will not be used if you vote in person. Please check the meeting materials for any special requirements for meeting attendance and how to obtain directions to the meeting.

    a

    Control Number:


     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting To Be Held on June 26, 2025:

     

    (1)
    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    (2)
    The Proxy Statement and 2024 Annual Report on Form 10-K are available at https://annualgeneralmeetings.com/crdf2025

     

    (3)
    If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before June 12, 2025 to facilitate timely delivery.

     

     

    To request a paper copy of these items:

     

    o
    Call our toll-free number – 1-800-785-3033; or
    o
    Visit our website at https://annualgeneralmeetings.com/crdf2025; or
    o
    Send us an e-mail at [email protected].

     

    Please clearly identify the items you are requesting; Cardiff Oncology, Inc., and your name along with the Control Number

    located in the lower right hand corner of this notice and the name and address to which the materials should be mailed.

     

     

    By Order of the Board of Directors

     

    /s/ Dr. Rodney S. Markin MD, Ph.D. Chairman of the Board of Directors

    a

    Control Number:


     

    img232721228_1.jpg

     

     


     

    img232721228_2.jpg

     

     


    Get the next $CRDF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRDF

    DatePrice TargetRatingAnalyst
    1/5/2026$12.00Outperform
    Noble Capital Markets
    7/8/2025$19.00Buy
    Ladenburg Thalmann
    6/24/2025$3.50Hold
    Jefferies
    9/6/2024$8.00Buy
    Craig Hallum
    2/28/2022$26.00 → $25.00Buy
    HC Wainwright & Co.
    1/5/2022Outperform
    William Blair
    12/8/2021$19.00Outperform
    Robert W. Baird
    12/8/2021$19.00Outperform
    Baird
    More analyst ratings

    $CRDF
    SEC Filings

    View All

    Cardiff Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

    1/27/26 4:01:24 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

    11/6/25 4:08:38 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Cardiff Oncology Inc.

    10-Q - Cardiff Oncology, Inc. (0001213037) (Filer)

    11/6/25 4:00:49 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ladenburg Thalmann initiated coverage on Cardiff Oncology with a new price target

    Ladenburg Thalmann initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $19.00

    7/8/25 8:35:06 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Cardiff Oncology with a new price target

    Jefferies initiated coverage of Cardiff Oncology with a rating of Hold and set a new price target of $3.50

    6/24/25 8:00:04 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Lindsay Brigitte Ute claimed ownership of 27,431 shares (SEC Form 3)

    3 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/9/26 4:00:10 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Pace Gary W bought $710,500 worth of shares (290,000 units at $2.45), increasing direct ownership by 26% to 1,330,676 units (SEC Form 4)

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    7/31/25 4:05:05 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sidhu Roger

    3 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    7/8/25 4:05:06 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDF
    Financials

    Live finance-specific insights

    View All

    Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

    - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in the Journal of Clinical Oncology – - Onvansertib continues to be safe and well-tolerated – - Company expects to provide final data and registrational plans in first half of 2026 – - Company to h

    1/27/26 7:05:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

    – Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. "This quarter was mar

    11/6/25 4:05:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

    – Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib continues to be well-tolerated and demonstrates a dose dependent response for all endpoints including ORR, early tumor shrinkage and depth of response – – Company will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today a

    7/29/25 4:07:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pace Gary W bought $710,500 worth of shares (290,000 units at $2.45), increasing direct ownership by 26% to 1,330,676 units (SEC Form 4)

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    7/31/25 4:05:05 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    12/18/24 4:37:28 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    12/16/24 5:00:03 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

    - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in the Journal of Clinical Oncology – - Onvansertib continues to be safe and well-tolerated – - Company expects to provide final data and registrational plans in first half of 2026 – - Company to h

    1/27/26 7:05:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

    VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last month, ushering in a new clinical paradigm for patients with historically resistant tumors [1]. Separately, the agency fast-tracked an experimental pancreatic cancer therapy based on early trial results showing tumors shrinking in nearly a third of patients[2]. These regulatory milestones position immunotherapy platforms capable of unlocking durable responses across multiple gastrointestinal malignancies as the next wave of commercial opportunity, drawing attention to developer

    12/12/25 10:31:03 AM ET
    $AGEN
    $CRDF
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CRDF
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

    First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q

    5/4/23 4:10:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

    Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as

    2/2/23 8:00:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

    SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

    2/6/24 4:01:34 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

    SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

    2/14/23 12:47:09 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cardiff Oncology Inc.

    SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)

    1/26/23 1:30:22 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care